Group 1 - The company, Jinghua Pharmaceutical, announced that its subsidiary, Shandong Luhuasenxuan New Materials Co., Ltd., led the formulation of the industry standard for "1,3-Dioxolane" [1] - The industry standard has been approved by the National Standardization Administration and will be officially implemented on March 1, 2026 [1]

Group 1 - The core point of the article is that the industry standard for "1,3-Dioxolane" has been approved by the National Standardization Administration and will be implemented starting March 1, 2026 [1] Group 2 - The standard was led by Shandong Luhuasenxuan New Materials Co., Ltd., a subsidiary of Jinghua Pharmaceutical [1] - The announcement was made by the Ministry of Industry and Information Technology [1]

精华制药公告，近日，由公司孙公司山东鲁化森萱新材料有限公司牵头制定的《13-二氧戊环》行业标 准（标准号：HG/T6387-2025）通过国家标委会评审，并经中华人民共和国工业和信息化部发布公告， 该标准于2026年3月1日起正式实施。 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-036 精华制药集团股份有限公司 关于孙公司牵头制定产品行业标准的公告 公司将以此行业标准发布、实施为新的起点，不断提高产品质量和管控措施， 进一步树立公司品牌形象，助推企业高质量发展。 特此公告。 精华制药集团股份有限公司董事会 2025 年 9 月 17 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 近日，由公司孙公司山东鲁化森萱新材料有限公司（以下简称"鲁化森萱"） 牵头制定的《1,3-二氧戊环》行业标准（标准号：HG/T6387-2025）通过国家标 委会评审，并经中华人民共和国工业和信息化部发布公告，该标准于 2026 年 3 月 1 日起正式实施。 ...

Core Viewpoint - The company, Jinghua Pharmaceutical, confirmed that its subsidiary, Luhua Senxuan, is a major domestic supplier of dioxane, which is currently not used in solid-state batteries [1] Group 1 - Jinghua Pharmaceutical responded to investor inquiries on September 12 regarding its subsidiary's production of dioxane [1] - Luhua Senxuan is identified as one of the main suppliers of dioxane in China [1]

Group 1 - The core point of the article is that Jinghua Pharmaceutical (002349.SZ) has clarified that its subsidiary, Luhua Senxuan, is not currently using dioxane in solid-state batteries, while the company is one of the major suppliers of dioxane in China [1]

Core Viewpoint - The company, Jinghua Pharmaceutical, confirmed that its subsidiary, Luhua Senxuan, does not currently use dioxane for solid-state batteries, although it is one of the major suppliers of dioxane in China [2] Group 1 - Investors inquired about the potential use of dioxane produced by Luhua Senxuan in solid-state batteries and its market share in the industry [2] - Jinghua Pharmaceutical stated that dioxane is not currently utilized in solid-state batteries [2] - The company is recognized as one of the main suppliers of dioxane in the domestic market [2]

Group 1 - The core inquiry from investors is about the annual production capacity of 2,5-dimethylfuran produced by the subsidiary Luhua Senxuan and whether there are plans for production expansion [2] - Luhua Senxuan primarily uses 2,5-dimethylfuran for the synthesis of urea-formaldehyde resin, with a portion utilized in the electrolyte for lithium iron phosphate batteries, but it is currently not used in solid-state batteries [2]

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]

Core Viewpoint - The company demonstrates resilience and growth potential in a complex industry environment, with steady revenue growth, significant cash flow improvement, and enhanced competitiveness of core products, alongside advancing internationalization and R&D innovation [1]. Financial Performance - For the first half of 2025, the company achieved revenue of 731 million yuan, a year-on-year increase of 1.54%; net profit attributable to shareholders was 131 million yuan, with a net profit of 127 million yuan after excluding non-recurring gains and losses, indicating solid profitability in core operations [2]. - The net cash flow from operating activities surged by 31.87% to 128 million yuan, reflecting improved operational quality and enhanced capital management efficiency [2]. Core Product Strength - Sales revenue from traditional Chinese medicine preparations grew by 12.45% year-on-year to 287 million yuan, serving as a key support for performance [3]. - Key products such as "Wang's Baochi Pill," "Jide Sheng Snake Medicine Tablets," and "Zheng Chai Hu Drink Granules" continue to gain clinical and market recognition due to their unique efficacy and strong brand heritage [3]. - "Wang's Baochi Pill" was included in the "International Clinical Practice Guidelines for Functional Dyspepsia in Traditional Chinese Medicine (2025 Edition)," enhancing its international influence [3]. International Expansion - The company actively expanded its overseas market, achieving self-operated export sales of 11.3 million USD, a year-on-year increase of 16% [4]. - Several raw material drug varieties have received FDA and CEP certifications, gaining international quality recognition [4]. R&D and Capacity Development - The company places high importance on R&D investment, collaborating with universities on various pharmacological and clinical research projects [5]. - The approval of new indications for "Diphenhydramine Hydrochloride Tablets" by the National Medical Products Administration further enriches the product line [5]. - Projects for traditional Chinese medicine preparation production bases, GMP certification upgrades, and energy-saving renovations are progressing steadily, laying the foundation for future capacity release and quality upgrades [5]. Cost Reduction and Efficiency Improvement - Through process optimization, intelligent equipment upgrades, and procurement cost control, the company achieved cost reductions exceeding 5 million yuan in the first half of the year [6]. - A successful stock incentive plan was implemented in May, granting 15.494 million restricted shares to 105 core employees, effectively motivating the team for long-term development [6]. Social Responsibility - The company continues to promote the construction of GAP bases for Chinese medicinal materials in Gansu Longxi, adopting a "leading enterprise + base + cooperative" model to boost local farmers' income [7]. - During the reporting period, the company procured local medicinal materials worth 30.946 million yuan, creating over 70 jobs, showcasing the responsibility and commitment of state-owned enterprises [7].